FOR THE TREATMENT OF INSOMNIA

Discover a surprisingly unique sleep agent

DORAL®
(quazepam tablets, USP)®

Uniquely Selective
Uniquely BZ₁ selective

Doral® (quazepam tablets, USP)—the only benzodiazepine that provides BZ₁ receptor selectivity¹

- BZ₁ receptor selectivity offers the benefits of a hypnotic agent without many of the drawbacks of typical benzodiazepines²
- BZ₁ receptors are believed to be associated with sleep function²

Doral is effective for sleep onset and maintenance⁴

- After Doral was discontinued, sleep onset and total awake time remained significantly lower than the pretreatment period³

Efficacy and safety confirmed in clinical studies involving more than 4,300 patients⁴

Favorable safety profile

- No transient sleep disturbances, such as rebound insomnia, were observed after withdrawal during clinical trials¹⁵
- In clinical trials, the most common adverse events were daytime drowsiness (12.0%) and headache (4.5%)⁵
Relative abuse liability of common sleep agents

![Bar chart showing relative abuse liability of common sleep agents](image)


Relative abuse liability comprises an assessment of the likelihood of abuse. Scores show the mean percentage of maximum possible score based on animal drug self-administration, human liking/reinforcement, and actual abuse.

Effect on cognitive-neuromotor performance

![Graph showing effect on cognitive-neuromotor performance](image)


*Using a numeric keypad, subjects were given 90 seconds to enter a geometric pattern associated with one of the nine digits displayed on a video screen—the object being to enter as many as possible. The dependent measures were the number of geometric patterns the subjects attempted to enter and the number of patterns the subjects entered correctly.
For the effective treatment of insomnia

- Acts selectively on BZ₁ receptors¹
- Highly effective at inducing and maintaining sleep³
- Favorable safety profile, with no rebound insomnia observed in clinical trials¹,⁵

Doral is available as a 15-mg tablet

For more information, go to www.DoralForSleep.com

Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Doral has been classified as a Schedule IV controlled substance. Patients receiving Doral should be cautioned about possible combined effects with alcohol and other CNS depressants.

Please see accompanying full prescribing information.